NEW YORK (GenomeWeb News) – Rosetta Genomics and its research collaborators have published in the Journal of Clinical Oncology data from a study showing that the same biomarker used in the firm's miRNA-based test for squamous lung cancer provided 96 percent sensitivity.
The study, which was posted online Monday on the journal's website, included 262 patients and was conducted by Rehovot, Israel-based Rosetta and researchers from Columbia University, NYU Cancer Institute, and Sheba Medical Center.
The firm said in a statement that it has shown that a single microRNA biomarker obtained from a routine pathological preparation of a biopsy identified squamous lung carcinomas with 96 percent sensitivity and 90 percent specificity.
Rosetta Genomics President and CEO Amir Avniel said that the study "strongly validates the microRNA technology that underlies our mirViw squamous test."
The firm offers the test through its CLIA-certified lab in Philadelphia. It launched the test, which is designed to differentiate squamous from non-squamous non-small cell lung cancer, in December.